HomeBUSINESS
BUSINESS

Romosozumab Shows Consistent Efficacy, Safety in Japanese Osteoporosis Patients: Amgen Astellas
(Oct.23.2017)

Amgen Astellas Biopharma said on October 20 that its anti-sclerostin monoclonal antibody romosozumab demonstrated consistent efficacy and safety in a subgroup of Japanese patients compared to the overall population of postmenopausal women with osteoporosis enrolled in a key PIII study ...
(LOG IN FOR FULL STORY)

News Calendar